EpiVario is rooted in its expertise in epigenetics. Using that rich source of learning, we are revolutionizing therapies for psychiatric disorders that plague a significant portion of the population, including those suffering from post-traumatic stress disorder, alcohol and drug addiction, Alzheimer’s disease, and dementia.

EpiVario Team

EpiVario was founded by epigeneticists at the University of Pennsylvania with the goal of developing products to provide novel treatments for many unmet needs in psychiatric disease.

CoFounder Shelley Berger, PhD

Daniel S. Och University Professor
University of Pennsylvania

CoFounder Philipp Mews, PhD

Instructor, Neuroscience Dept.
Friedman Brain Institute at Mt Sinai

CEO Thomas Kim

Biotech Executive & Corp Attorney
Inovio Pharmaceuticals,
DuPont, G.D. Searle